Application of a novel boronated porphyrin (H₂OCP) as a dual sensitizer for both PDT and BNCT.
OBJECTIVE
Boronated porphyrins have emerged as promising dual sensitizers for use in both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and easy synthesis with high boron content. Octa-anionic 5,10,15,20-tetra[3,5-(nido-carboranylmethyl)phenyl] porphyrin (H₂OCP) is a boronated porphyrin having eight boron clusters linked to the porphyrin ring. To evaluate H₂OCP's applicability to both PDT and BNCT, we performed an in vitro and ex vivo study using F98 rat glioma cells.


METHODS
We examined the time-dependent cellular uptake of H₂OCP by measuring the boron concentration over time, and compared the cellular uptake/clearance of boron after exposure to H₂OCP in conjunction with boronophenylalanine (BPA) and sodium borocaptate (BSH), both of which are currently used in clinical BNCT studies. We evaluated the cytotoxicity of H₂OCP-mediated PDT using a colony-forming assay and assessed the tumorigenicity of the implantation of pre-treated cells using Kaplan-Meier survival curves. Fluorescence microscopy was also performed to evaluate the cellular uptake of H₂OCP.


RESULTS
H₂OCP accumulated within cells to a greater extent than BPA/BSH, and H₂OCP was retained inside the cells to approximately the same extent as BSH. The cell-surviving fraction following laser irradiation (8 J/cm², 18 hours after exposure to 10 µg B/ml H₂OCP) was <0.05. The median survival times of the pre-treated cell-implanted rats were longer than those of the untreated group (P < 0.05). The fluorescence of H₂OCP was clearly demonstrated within the tumor cells by fluorescence microscopy.


CONCLUSIONS
H₂OCP has been proven to be a promising photosensitizer for PDT. H₂OCP has also been proposed as a potentially effective replacement of BPA or BSH, or as a replacement of both BPA/BSH. Our study provides more evidence that H₂OCP could be an effective novel dual sensitizing agent for use in both PDT and BNCT.
Department of Neurosurgery, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan.
Ryo
R
Hiramatsu
Shinji
S
Kawabata
Shin-Ichi
S
Miyatake
Toshihiko
T
Kuroiwa
Michael W
MW
Easson
M Graça H
MG
Vicente
D000818:Animals; D001896:Boron Compounds / Q000627:therapeutic use*; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D005910:Glioma / Q000628:therapy; D010778:Photochemotherapy / Q000379:methods*; D011166:Porphyrins / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D051381:Rats; D014407:Tumor Cells, Cultured
C558281:5,10,15,20-tetra(3,5-(nido-carboranylmethyl)phenyl)porphyrin; D001896:Boron Compounds; D011166:Porphyrins; D011838:Radiation-Sensitizing Agents
Oncologist. 2006 Feb;11(2):165-80
16476837
Bioorg Med Chem. 2005 Mar 1;13(5):1633-40
15698781
J Neurosurg. 1980 Dec;53(6):808-15
7003068
Mol Chem Neuropathol. 1994 Feb-Apr;21(2-3):337-52
8086042
Cancer. 1992 Dec 15;70(12):2995-3007
1451084
Chemistry. 2007;13(32):9035-42
17676575
Cancer Res. 2004 Apr 1;64(7):2317-23
15059878
J Neurosurg. 2000 Dec;93(6):1003-13
11117842
J Neurosurg. 1995 Jul;83(1):86-92
7782856
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):247-52
16111595
Photochem Photobiol Sci. 2006 Jan;5(1):39-50
16395426
Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):643-52
7928496
J Radiat Res. 2009 Jan;50(1):51-60
18957828
Med Phys. 1990 Nov-Dec;17(6):1045-52
2280734
J Neurooncol. 2009 Jan;91(2):199-206
18813875
J Natl Cancer Inst. 1998 Jun 17;90(12):889-905
9637138
J Photochem Photobiol B. 1996 Nov;36(2):157-68
9002253
J Med Chem. 1967 Jul;10(4):714-7
6037065
Clin Cancer Res. 2005 Jun 1;11(11):3987-4002
15930333
Br J Radiol. 2004 Jul;77(919):573-80
15238404
J Neurooncol. 1998 Jan;36(1):91-102
9525831
Anticancer Agents Med Chem. 2006 Mar;6(2):145-57
16529537